Business
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
BERLIN, January 27, 2026--Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking sessions at the upcoming American Stroke Association’s International Stroke Conference (ISC) 2026. The conference will be held February 4-6 in New Orleans, Louisiana, USA.
About this update from Bayer Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/f6dd8244cd52a371801159e2021970aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3WLw.M_9BWtWq5WtiX..FA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f6dd8244cd52a371801159e2021970aa","width":400,"height":400}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Findings from OCEANIC-STROKE, including the main results and a prespecified subgroup analysis, will be presented for the first time during two late-breaking sessions at the International Stroke Conference 2026","length":209,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Asundexian is an investigational once daily, oral Factor XIa (FXIa) inhibitor","length":77,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":286,"olType":false},{"type":"text","content":"BERLIN, January 27, 2026--(BUSINESS WIRE)--Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking sessions at the upcoming American Stroke Association’s International Stroke Conference (ISC) 2026. The conference will be held February 4-6 in New Orleans, Louisiana, USA.","length":404,"tagName":"p"},{"type":"text","content":"The research to be presented demonstrates the longstanding commitment of Bayer as a leader in cardiovascular and cerebrovascular medicine, advancing innovation in thrombosis prevention.","length":185,"tagName":"p"},{"type":"text","content":"In November 2025, Bayer announced the OCEANIC-STROKE study met its primary efficacy and safety endpoints. OCEANIC-STROKE is a multicenter, international, randomized, placebo-controlled, double-blind, parallel group and event-driven study, that enrolled over 12,300 patients.","length":274,"tagName":"p"},{"type":"text","content":"Bayer late-breaking presentations on the Phase III study OCEANIC-STROKE at ISC 2026 include:","length":92,"tagName":"p"},{"type":"text","content":"Late Breaker: Factor XIa Inhibition with Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEAN...